Congress Materials

XIFAXAN®

(rifaximin) 550 mg tablets

IBS-D

American College of Gastroenterology (ACG) Annual Scientific Meeting 2022—October 21–26, 2022, Charlotte, NC

Rifaximin improves both fecal urgency and stool consistency in adults with irritable bowel syndrome with diarrhea: a composite endpoint analysis of two randomized, phase 3 trials

Cash BD, et al.

The strong association between bloating, abdominal pain, and global irritable bowel syndrome (IBS) symptom scores in IBS with diarrhea: a phase 3 trial pooled correlation analysis of individual symptoms

Staller K, et al.

AAFP FMX 2022—September 20–23, 2022, Washington, DC

A new trisymptom composite endpoint to evaluate the efficacy of rifaximin for multiple symptoms of irritable bowel syndrome with diarrhea: a pooled analysis of two randomized, phase 3 trials [Encore]

Lacy BE, et al.

Digestive Disease Week (DDW) 2022—May 21–24, 2022, San Diego, CA + Virtual

A new trisymptom composite endpoint to evaluate the efficacy of rifaximin for multiple symptoms of irritable bowel syndrome with diarrhea: a pooled analysis of two randomized, phase 3 trials

Lacy BE, et al.

Society of General Internal Medicine (SGIM) 2022 Annual Meeting—April 6–9, 2022, Orlando, FL

Rifaximin improves both abdominal pain and bloating in patients with irritable bowel syndrome with diarrhea: a composite endpoint analysis of two phase 3, randomized, placebo-controlled trials [Encore]

Lacy BE, et al.

Digestive Disease Week (DDW) 2021—May 21–23, 2021, Virtual

Rifaximin improves both abdominal pain and bloating in patients with irritable bowel syndrome with diarrhea: a composite endpoint analysis of two phase 3, randomized, placebo-controlled trials

Lacy BE, et al.

Rifaximin significantly improves bowel movement urgency in patients with irritable bowel syndrome with diarrhea: a pooled analysis of three phase 3 trials

Schoenfeld PS, et al.

AAFP FMX 2020—October 13–17, 2020, Virtual

Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults previously treated with other IBS medications [Encore]

Rao SSC, et al.

United European Gastroenterology (UEG) Week 2020—October 11–13, 2020, Virtual

Efficacy of rifaximin on bloating in patients with diarrhea‐predominant irritable bowel syndrome (IBS-D): a pooled analysis of three phase 3, randomized, placebo‐controlled trials

Lacy B, et al.

Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea in adults previously treated with other IBS medications [Encore]

Rao SSC, et al.

American Association of Nurse Practitioners (AANP) National Conference 2020—September 10, 2020–December 31, 2020, Virtual

Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults previously treated with other IBS medications [Encore]

Kassebaum A, et al.

Society of General Internal Medicine (SGIM) 2020 Annual Meeting—May 6-9, 2020, Virtual

Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea in patients receiving concomitant antidepressants

Laitman AP, et al.

Digestive Disease Week (DDW) 2020—May 2–5, 2020, Virtual

Pooled analysis of two phase 3, placebo-controlled studies assessing the impact of colonoscopy timing on rifaximin efficacy in irritable bowel syndrome with diarrhea (IBS-D)

Chang C, et al.

Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults previously treated with other IBS medications

Rao SSC, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2019—October 25–30, 2019, San Antonio, TX

Impact of colonoscopy timing on rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D)

Lacy BE, et al.

AAFP FMX 2019—September 24–28, 2019, Philadelphia, PA

Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]

Lacy BE, et al.

American Neurogastroenterology and Motility Society 2019 Annual Meeting—August 16–18, 2019, Chicago, IL

Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]

Lacy BE, et al.

Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline (BL) pain severity [Encore]

Lembo A, et al.

American Association of Nurse Practitioners (AANP) National Conference 2019—June 18–23, 2019, Indianapolis, IN

Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline pain severity [Encore]

Allen C, et al.

Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]

Lorenzen S, et al.

Digestive Disease Week (DDW) 2019—May 18–21, 2019, San Diego, CA

Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]

Lacy BE, et al.

Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline pain severity [Encore]

Lembo A, et al.

AAFP FMX 2018—October 9–13, 2018, New Orleans, LA

Rifaximin for irritable bowel syndrome-related bloating

Lacy BE, et al.

Rifaximin for abdominal pain in irritable bowel syndrome with diarrhea

Lembo A, et al.

Impact of prior irritable bowel syndrome medication use on rifaximin

Lembo A, et al.

Rifaximin safety profile in irritable bowel syndrome [Encore]

Weinstock LB, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2018—October 5–10, 2018, Philadelphia, PA

Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response

Lacy BE, et al.

Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline pain severity

Lembo A, et al.

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference 2018—September 7–9, 2018, Las Vegas, NV

Characterization of abdominal pain response in patients with irritable bowel syndrome with diarrhea treated with rifaximin [Encore]

Faiman O, et al.

Efficacy of rifaximin on bloating in patients with irritable bowel syndrome with diarrhea: a pooled analysis of three phase 3, randomized, placebo-controlled trials [Encore]

Lacy BE, et al.

American Association of Nurse Practitioners (AANP) National Conference 2018—June 26–July 1, 2018, Denver, CO

Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome (IBS) treated with rifaximin [Encore]

Lembo A, et al.

Digestive Disease Week (DDW) 2018—June 2–5, 2018, Washington, DC

Efficacy of rifaximin on bloating in patients with diarrhea‐predominant irritable bowel syndrome (IBS‐D): a pooled analysis of three phase 3, randomized, placebo‐controlled trials

Lacy BE, et al.

Efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and prior use of IBS medications

Lembo AJ, et al.

Rifaximin repeat treatment for diarrhea-predominant irritable bowel syndrome (IBS-D) and impact on Clostridium difficile infection development

Pimentel M, et al.

Lack of development of opportunistic infections, including candidiasis, in patients with diarrhea-predominant irritable bowel syndrome receiving repeat treatment with rifaximin

Pimentel M, et al.

Characterization of long-term rifaximin responders from a phase 3, randomized, double-blind, placebo-controlled repeat treatment trial for diarrhea-predominant irritable bowel syndrome (IBS-D)

Weinstock LB, et al.

American Academy of Pain Medicine (AAPM) 34th Annual Meeting—April 25–29, 2018, Vancouver, Canada

Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) treated with rifaximin [Encore]

Lembo A, et al.

Society of General Internal Medicine (SGIM) 2018 Annual Meeting—April 11–14, 2018, Denver, CO

Rifaximin has a favorable safety and tolerability profile for the treatment of patients with diarrhea-predominant irritable bowel syndrome

Weinstock LB, et al.

World Congress of Gastroenterology (WCG) at ACG 2017—October 13–18, 2017, Orlando, FL

Responders analysis in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) treated with rifaximin

Lembo AJ, et al.

Assessing the efficacy of rifaximin in diarrhea-predominant irritable syndrome (IBS-D): a post hoc analysis of two phase 3, randomized, placebo-controlled trials

Pimentel M, et al.

PAINWeek 2017—September 5–9, 2017, Las Vegas, NV

Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome treated with rifaximin [Encore]

Lembo A, et al.

American Association of Nurse Practitioners (AANP) National Conference 2017—June 20–25, 2017, Philadelphia, PA

Safety and tolerability of rifaximin in the treatment of irritable bowel syndrome (IBS): a pooled analysis of 4 randomized, placebo-controlled trials [Encore]

Lembo A, et al.

American Academy of Physician Assistants (AAPA) Conference 2017—May 15–19, 2017, Las Vegas, NV

Safety and tolerability of rifaximin in the treatment of irritable bowel syndrome (IBS): a pooled analysis of 4 randomized, placebo-controlled trials [Encore]

Landers M, et al.

Digestive Disease Week (DDW) 2017—May 6–9, 2017, Chicago, IL

Impact of rifaximin on health-related quality of life in patients with diarrhea-predominant irritable bowel syndrome

Cash BD, et al.

Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome treated with rifaximin

Lembo AJ, et al.

Sustained response and predictors of sustained response in patients who respond to multiple courses of rifaximin for diarrhea-predominant irritable bowel syndrome

Pimentel M, et al.

Society of General Internal Medicine (SGIM) 2017 Annual Meeting—April 19–22, 2017, Washington, DC

Assessment of the safety and tolerability of the antibiotic rifaximin for irritable bowel syndrome (IBS): a pooled analysis of three phase 3 studies [control ID #2699361]

Chang C, et al.

Third Annual Translational Microbiome Conference—April 11–13, 2017, Boston, MA

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhea-predominant irritable bowel syndrome

Fodor A, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2016—October 14–19, 2016, Las Vegas, NV

Analysis of potential predictors of symptom recurrence in patients treated with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D)

Lembo AJ, et al.

Safety and tolerability of rifaximin in the treatment of irritable bowel syndrome (IBS): a pooled analysis of 4 randomized, placebo-controlled trials

Lembo AJ, et al.

Improvements over time in individual diarrhea-predominant irritable bowel syndrome symptoms (IBS-D) with rifaximin repeat treatment

Pimentel M, et al.

Efficacy of rifaximin on bowel movement urgency in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): a pooled analysis of 3 phase 3 trials

Pimentel M, et al.

Second Federation of Neurogastroenterology and Motility Meeting (FNM) 2016—August 25–28, 2016, San Francisco, CA

Stool microbiota characterization in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) receiving repeat rifaximin

Pimentel M, et al.

WAO Symposium on Food Allergy and the Microbiome 2015—December 5–6, 2015, Miami, FL

Characterization of stool microbiota in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) receiving repeat treatments with rifaximin in the TARGET 3 study

Pimentel M, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2015—October 16–21, 2015, Honolulu, HI

Infection-related safety profile of rifaximin repeat treatment for diarrhea-predominant irritable bowel syndrome (IBS-D)

Chey WD, et al.

Antibiotic susceptibility of skin swab Staphylococcus isolates from patients with diarrhea-predominant irritable bowel syndrome (IBS-D) treated with repeat courses of rifaximin show no evidence of resistance

Schoenfeld P, et al.

Digestive Disease Week (DDW) 2015—May 17–19, 2015, Washington, DC

Improvements in IBS-related quality of life in a randomized, controlled repeat treatment trial (TARGET 3) of rifaximin for IBS-D

Cash BD, et al.

Comparison of symptoms, health care utilization, and treatment in diagnosed and undiagnosed patients with IBS with diarrhea

Chang L, et al.

Characterizing the effect of rifaximin on individual symptoms of IBS-D: findings from the open-label phase of TARGET 3

Chang L, et al.

Enduring effects following a course of rifaximin therapy in patients with IBS-D: incremental benefit upon repeat treatment

Lacy BE, et al.

Safety and tolerability of rifaximin in a repeat treatment study in subjects with IBS-D: results from TARGET 3 [Encore]

Lembo A, et al.

Durability of benefit in IBS-D patients responding to a 2-week course of rifaximin: results from TARGET 3

Pimentel M, et al.

Characterization of stool microbiota in subjects with IBS-D receiving repeat treatments with rifaximin in the TARGET 3 study

Pimentel M, et al.

Rifaximin for IBS-D: consistent treatment effect across demographic and baseline disease characteristics

Schoenfeld P, et al.

Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2015—April 7–10, 2015, San Diego, CA

Treatment patterns for Xifaxan (rifaximin) in patients with irritable bowel syndrome: a healthcare claims analysis [abstract K6 ; page S57]

Kirkwold JL, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2014—October 17–22, 2014, Philadelphia, PA

Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET 3 study

Lembo A, et al.

View product- and therapeutic area—related publications appearing in peer-reviewed journals.

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)